Poolbeg Pharma, a clinical-stage biopharmaceutical company focused on infectious diseases and other epidemics with high unmet medical need, is using CytoReason to develop the world’s first influenza artificial intelligence (“AI”) program. announced significant progress. Since March 2022, Pourbegg said he has been working with CytoReason.
Pourbegg’s own disease progression data from the influenza human challenge trial was combined with CytoReason’s extensive repository of curated disease data and analyzed using CytoReason’s industry-leading AI-driven platform. This analysis has led to the discovery of multiple novel drug targets for the treatment of influenza.
Identification of drug targets from this unique data set has been successful, with p38 MAP kinase inhibited by POLB 001 identified as the cause of severe influenza, but this requires years of manual work. analysis was required. But with CytoReason’s cutting-edge AI technology, Pourveg identified multiple novel drug targets in just 15 months. In addition, CytoReason’s analysis independently confirmed the importance of his p38 MAP his kinase pathway in influenza, providing further validation of Poolbeg’s POLB 001 program.
We are actively seeking the most effective ways to further develop novel drug targets to create value and look forward to updating our shareholders on the progress of this program in the near future. I’m here. This marks the second success of Pourbeg’s AI program following the identification of a potential drug candidate for respiratory syncytial virus (RSV) announced in December 2022.
Our collaboration with CytoReason has allowed Poolbeg to be at the forefront of AI drug discovery. CytoReason’s exhaustive search for a wealth of unique data from human challenge studies has led to a greater understanding of influenza and the identification of multiple novel influenza drug targets. There is a great unmet need for new and better treatments for vulnerable flu patients, and this represents a major milestone in delivering new treatments that can improve patient outcomes and global health. ”
Dr. Jeremy Skillington, Chief Executive Officer of Poolbeg Pharma
CytoReason CEO David Harel said: “Once again, we are excited to leverage CytoReason’s computational disease models to extract insights.s Data from Pourbegg’s unique human challenge data can optimize the target discovery process. More importantly,Such impressive results would not be possible without a transparent commitment.rhinocerosand mutualsex of both teams”
